Efficacy and safety comparison of regorafenib and fruquintinib in metastatic colorectal cancer-An observational cohort study in the real world
Clinical Colorectal Cancer — Zhang Q, Chen M, Wang Z, et al. | January 21, 2022
In the treatment of metastatic colorectal cancer (CRC), regorafenib and fruquintinib demonstrated similar efficacy and toxicity profiles with various frequency. Longer overall survival (OS) was obtained with regorafenib followed by fruquintinib than the reverse, but the sequence needs to be further confirmed.
In this ambispective observational cohort study, a total of 366 patients with metastatic CRC who received regorafenib (n=260) or fruquintinib (n=106) were analyzed.
Median time-to-treatment failure (regorafenib 2.7 months vs fruquintinib 3.1 months) or median OS (regorafenib 13.8 months vs fruquintinib 11.3 months) did not differ between the two treatment arms.
The longer OS was experienced in relation to regorafenib followed by fruquintinib vs the reverse (28.1 months vs 18.4 months).
Regorafenib was tolerable in most cases at a reduced dose (93.1%), and the majority of patients tolerated fruquintinib at a standard dose (68.9%).
Similar incidences for most adverse events were noted between the two groups.
In the regorafenib group, any grade of hand-foot skin reaction and hyperbilirubinemia occurred more frequently, and ≥grade 3 hypertension was more common in the fruquintinib group.